[Click eStock] "L&K, Spinal Implant Product's Entry into US Market Expected to Trigger Quantum Leap in Performance"

[Asia Economy Reporter Yoo Hyun-seok] KTB Investment & Securities analyzed on the 19th that L&K Bio is expected to achieve a quantum jump in performance with the entry of new high-margin products into the U.S. market. No investment opinion or target price was provided.

L&K Bio is a medical device company specializing in the development and manufacturing of spinal implants. It has product lineups for the spine, cervical spine, and lumbar spine. As a new product, it developed three types of Expandable Cage and completed FDA approval in September last year.

Kim Jae-yoon, a researcher at KTB Investment & Securities, said, "The Expandable Cage is an artificial disc that can be height-adjusted to fit the body shape, offering excellent expandability. Accordingly, it commands a price about five times higher than existing cages, and there is no need to stock different sizes, enabling high profit margins."

He added, "All three types of Expandable Cage?xt, xl, and xtp?have received FDA approval according to the surgical direction, making entry into the U.S. spinal implant market highly likely. Although the Expandable Cage is a high-priced product exceeding $5,000 per unit when sold directly to hospitals in the U.S., L&K Bio is understood to be seeking exclusive supply contracts with large medical device companies (such as Stryker and Zimmer) to ensure stable supply in the U.S. market. When supplying to large clients, the typical selling price per unit is expected to be around $1,200 to $1,800," he evaluated.

In particular, Researcher Kim expected high growth potential for L&K Bio based on the Expandable Cage. He said, "Considering that contracts with large domestic medical device companies supply quantities on a state basis, L&K Bio's annual supply volume is expected to reach approximately 80 billion KRW. Therefore, if L&K Bio supplies the Expandable Cage to the U.S. market through large medical device companies, a quantum jump in performance will begin," he emphasized. He added, "However, the company's annual capacity is about 50 billion KRW, so if supply to global companies begins, expansion will need to precede."

This content was produced with the assistance of AI translation services.